October 2026
Whitepaper
Translational Data and the Next Era of Drug Development
Drug development does not lack data. It lacks consistently decision-grade translational evidence.

Notes from a long-term investor in science and technology. We’re interested in giving a lasting home to technologies that have created value for years, even when the companies behind them are small.
October 2026
Whitepaper
Drug development does not lack data. It lacks consistently decision-grade translational evidence.
May 2025
Published
One of the most critical—and overlooked—skills in building a business isn’t perfecting your pitch; it’s learning to truly listen.
April 2025
Published
At RocketBio, we invest exclusively in tissue engineering and regenerative medicine companies — not for the quick win, but for the long-term journey.
March 2025
Published
Long-term ownership means the people and the product are not put on a timer for the next sale.
March 2025
Published
The companies worth holding were not built in rooms that only investors sit in.